miRNA, phytometabolites and disease: Connecting the dots

Abstract

AbstractmiRNAs are tiny noncoding ribonucleotides that function as critical regulators of gene‐expression in eukaryotes. A single miRNA may be involved in the regulation of several target mRNAs forming complex cellular networks to regulate diverse aspects of development in an organism. The deregulation of miRNAs has been associated with several human diseases. Therefore, miRNA‐based therapeutics is gaining interest in the pharmaceutical industry as the next‐generation drugs for the cure of many diseases. Medicinal plants have also been used for the treatment of several human diseases and their curative potential is attributed to their reserve in bioactive metabolites. A role for miRNAs as regulators of the phytometabolic pathways in plants has emerged in the recent past. Experimental studies have also indicated the potential of plant encoded secondary phytometabolites to act as cross‐regulators of mammalian miRNAs and transcripts to regulate human diseases (like cancer). The evidence for this cross‐kingdom gene regulation through miRNA has gathered considerable enthusiasm in the scientific field, even though there are on‐going debates regarding the reproducibility and the effectiveness of these findings. In this review, we provide information to connect the medicinal and gene regulatory properties of secondary phytometabolites, their regulation by miRNAs in plants and their effects on human miRNAs for regulating downstream metabolic or pathological processes. While further extensive research initiatives and good clinical evidence are required to prove or disapprove these findings, understanding of these regulations will have important implications in the potential use of synthetic or artificial miRNAs as effective alternatives for providing health benefits.